802 results about "Drug efficiency" patented technology

The invention provides a ziconotide nasal-brain delivery preparation which is high in brain targeting, safe and noninvasive and directly enters the brain through nasal administration. The nasal-brain delivery preparation comprises an active component ziconotide and an absorption enhancer, wherein the absorption enhancer is selected from one or more of dodecyl-beta-D-maltoside (DDM), menthol, hydroxypropyl-beta-cyclodextrin (HP-beta-CD), sodium glycocholate (SGC) and related derivatives thereof. The absorption enhancer with a specific type and content and the ziconotide cooperate and act together, so that the ziconotide bypasses a blood brain barrier, enters the brain through a nasal olfactory mucous membrane, forms a medicine storage bank in an olfactory bulb, is slowly released to the brain and keeps a long-term medicine effect, and therefore, a traditional ziconotide intrathecal administration mode is abandoned; the ziconotide nasal-brain administration mode is created, and the ziconotide nasal-brain administration method is a new-generation therapy for pain diseases related to the central nervous system.

The invention relates to the technical field of medicine data analysis, in particular to a method, a system and equipment for generating a medicine relocation research report and a medium. According to the method for generating the drug relocation research report, a drug relocation request submitted by a pharmaceutical enterprise is decomposed into three sub-tasks of indication extension analysis, target matching analysis and drug effect simulation verification, and an indication extension analysis agent, a target matching analysis agent and a drug effect simulation verification agent are called respectively; the contribution value of each link is calculated through multi-agent cooperation, and finally a relocation research report containing potential rating and confidence evaluation is generated based on the drug-disease knowledge graph. By implementing the technical scheme provided by the invention, the efficiency and reliability of drug relocation analysis are improved, and scientific and credible decision support is provided for pharmaceutical enterprises.

The invention discloses a multi-target drug molecule generation model construction method and a multi-target drug design method, and relates to computer drug design and bioinformatics. Determining a corresponding two-dimensional molecular map based on the SMILES sequence; the fully-connected pharmacophore diagram and the two-dimensional molecular diagram are used as input of a GatedGCN module, each atomic node in the two-dimensional molecular diagram is connected with all pharmacophore nodes in the fully-connected pharmacophore diagram in message transmission, and information exchange between different nodes is achieved; the masked SMILES sequence serves as the input of an encoder, and the decoder generates an SMILES sequence conforming to pharmacophore characteristics in an autoregression mode; freezing the network parameters of the GatedGCN module and the encoder; and training the multi-target drug molecule generation model through the elite multi-target molecule set, and reversely optimizing and updating decoder network parameters according to an output result. According to the method, the model fully learns the multi-target molecular structure characteristics, and the multi-target drug molecule generation accuracy is improved.

The invention belongs to the technical field of nano-drugs, and discloses a multifunctional nano-drug delivery system for treating neovascular eye diseases and a preparation method of the multifunctional nano-drug delivery system. The nano drug delivery system disclosed by the invention is a composite nano preparation which takes dendritic mesoporous silica nanoparticles as a carrier and co-loads cerium zirconium oxide nano enzyme and an anti-VEGF (vascular endothelial growth factor) drug, various active oxygen can be efficiently removed, oxygen is continuously released through catalytic decomposition of hydrogen peroxide, a retina hypoxia microenvironment is improved, and the retina hypoxia effect is improved. According to the present invention, the anti-VEGF drug delivery system can reduce the oxidative stress induced retinal pigment epithelial cell apoptosis rate, reduce the inflammatory reaction, and simultaneously achieve the slow release and the controlled release of the anti-VEGF drug, and the drug effect maintenance time can achieve more than 60 days, such that the multi-target synergistic treatment can be achieved through the synergistic regulation of the multiple pathological links such as oxygen deficit-oxidative stress-inflammation-angiogenesis, and the anti-VEGF drug delivery effect can be achieved. The choroidal neovascularization can be effectively inhibited by single intravitreal injection, and a new strategy of multi-target collaborative treatment is provided for neovascular macular degeneration and other eye diseases.

The application provides sodium zirconium cyclosilicate with controlled particle size distribution, which has less particles less than 3 microns, thereby improving drug safety, and has more than 95% ZS-9 crystal form, thereby having high KEC, and ensuring drug efficacy. The application further provides a preparation method and use of the sodium zirconium cyclosilicate.

The invention discloses a detection method for rapid real-time drug effect evaluation and application of the detection method. The detection method comprises the following steps: providing a quantitative corresponding relation between a same-generation calibration change value of electrical characteristics caused by physiological changes such as cell same-representative characteristics and the like and the cell proliferation ability; adhering to-be-detected cells to the surface of the same membrane electrode; applying the medicine to be detected, and observing the same generation measurement change value of the electrical characteristics in a cell proliferation cycle; and based on the quantitative corresponding relationship, obtaining the drug effect of the corresponding real-time proliferation characteristic evaluation drug. According to the detection method provided by the invention, the physiological changes such as the same-representative characteristics of the adherent cells are monitored through the membrane electrode, and after the quantitative corresponding relation between the change indexes of the same-representative characteristics of the cells and the proliferation capacity of the cells is established, the cell proliferation capacity is detected; the change of the cell proliferation capacity can be predicted through physiological changes such as the same representative characteristics of the cells before proliferation and apoptosis of the cells, so that the judgment period of the influence of the medicine on the cells can be greatly shortened, and the progress of medicine evaluation and research and development can be remarkably accelerated.

The invention discloses a multi-target joint optimized antibiotic molecule design system and method applied to the field of biological medicine, and the method comprises the steps: obtaining FabI enzyme and AcrAB-TolC efflux pump structure data, extracting double-target space and physicochemical characteristics, and constructing a joint pharmacophore model containing a FabI inhibition domain and an efflux pump blocking domain; screening candidate molecules meeting a double-domain space matching threshold, screening high-affinity double-target molecules through conformation sampling and free energy calculation, and forming a lead compound library through multi-layer filtration of metabolic stability, membrane penetrability, quantum chemical properties and synthesis feasibility; carrying out electron effect, chain length or heteroatom fine tuning on dominant molecules through in-vitro bacteriostasis and efflux inhibition experiment feedback, and carrying out iterative optimization until MIClt is met; 2 [mu] g / mL and the efflux inhibition rate is gt; according to the present invention, the antibacterial effect and the drug resistance inhibition ability are significantly improved, the molecular synthesizability and the biological safety are ensured, and the engineering design new path is provided for the Gram-negative bacterium drug resistance crisis.

The invention discloses a composition containing a honeysuckle extract, a tablet and a production method thereof, and belongs to the technical field of medicines.The preparation method comprises the steps that pseudo-ginseng, honeysuckle and radix isatidis are dried and ground into powder, a hydrogel film coating with an environmental response function is prepared, and the hydrogel film coating has porosity and environmental tolerance, can improve the slow release performance of a medicine, and has a good application prospect. The active ingredient preservation time of the medicine is protected, and the medicine effect is prolonged; according to the hydrogel film coating, natural plant-derived polysaccharide and microcrystalline cellulose with excellent biocompatibility are used as raw materials, the raw materials are subjected to swelling treatment and then grafted with a polyethylene glycol-maleic anhydride copolymer, then an iron metal framework sensitive to the pH value is subjected to hydrothermal synthesis on the surface, the iron metal framework serves as a crosslinking center, a hydrogel film structure is generated through crosslinking to serve as the coating, and the hydrogel film coating is prepared. Therefore, the permeation resistance and mechanical strength of the coating are balanced, the swelling rate difference is avoided, the structural stability of the coating is guaranteed, and the tablet prepared from the coating can be used for treating cold and has a good drug effect.

The invention discloses a platelet growth factor derived polypeptide as well as a composition and application thereof. The amino acid sequence of the polypeptide is shown as Seq ID No: 1 (RP1601: LLKLLKKLLKKLLKK). KKIIKKL is used as a core active sequence, a variant library is designed by adopting a special design rule (AABB cycle rule), optimization is carried out by combining a polypeptide activity prediction system with a molecular docking technology, finally five candidate polypeptides are screened out, the polypeptide RP1601 has a better balance expression between drug effect and safety, and the polypeptide RP1601 is simple in structure, easy to synthesize and optimize and high in stability, and can be used for preparing a polypeptide RP1601. Therefore, the polypeptide is determined as an optimal candidate polypeptide; based on excellent anti-inflammatory, repair-promoting and anti-oxidation characteristics of the polypeptide, the invention further provides application of the polypeptide in cosmetics and medicines.

The invention provides a diketone biphenyl compound serving as a VAV1 degradation agent and application of the diketone biphenyl compound. Specifically provided are a compound represented by formula (I), a tautomer, a stereoisomer, a pharmaceutically acceptable salt or a prodrug thereof. The compound provided by the invention is good in drug effect and can be used for preparing drugs for treating or preventing VAV1 related diseases.

The invention relates to the technical field of elderly chronic disease medication management, and discloses an elderly chronic disease medication compliance intelligent reminding and management system. The system comprises an individualized medication modeling unit for establishing an individual pharmacodynamic model containing medication taboo and dosage rules based on an electronic health record of a patient and pharmacokinetic parameters; the multi-modal behavior sensing unit is used for collecting physiological data and movement tracks through wearable equipment, and generating a medication behavior sequence in combination with the record of the intelligent medicine box; the compliance deviation analysis unit is used for comparing an expected behavior with an actual behavior to calculate indexes such as a time matching degree and dose deviation; the risk decision engine unit is used for outputting an intervention level and a reminding strategy in combination with the deviation index, the physiological state and drug interaction; and the cross-platform collaborative execution unit triggers multi-channel reminding, medicine box locking and emergency contact notification. According to the system, the whole medication management process is intelligent, and the medication compliance and safety of the elderly patients are improved.

The invention relates to the technical field of medical instruments, in particular to a paclitaxel drug coating balloon dilatation catheter and a preparation method and application thereof.The paclitaxel drug coating comprises a substrate layer, a middle layer and an outer layer; the substrate layer comprises paclitaxel and a hydrophilic excipient; the middle layer comprises a lipophilic excipient and a temperature response type polymer; and the outer layer comprises a pH sensitive polymer. The substrate layer is combined with the surface of the balloon, so that excellent conveying stability is provided, the medicine is effectively prevented from falling off prematurely in the conveying process of the catheter, and the firmness of the coating is improved; a micropore network structure is formed in the middle layer, the network structure is expanded under the body temperature condition, the porosity is increased, slow release of the medicine is achieved, the absorption amount of the medicine on the blood vessel wall is effectively increased, and the medicine effect time is prolonged; the solubility of the outer layer is improved in a slightly acidic blood vessel wall environment, so that the release of the medicine is further promoted, and the effective release of the medicine on the blood vessel wall is ensured.

The invention discloses a microfluidic multi-organ tumor chip targeted drug test AIGC system, and relates to the technical field of medical drug test information processing. The microfluidic multi-organ tumor chip targeted drug test AIGC system comprises a multi-omics data acquisition module for acquiring and preprocessing disturbance response data and dynamic expression data; the disturbance response pre-screening module is used for carrying out strength evaluation on drug action strength and reconstructing channel mapping; the characteristic space reconstruction module is used for performing action analysis on the whole medicine action state and dynamically adjusting a liquid medicine blending rule; the drug effect prediction module is used for predicting and evaluating the response degree of the organoid under the intervention of the specific drug and deducing the individualized drug effect intensity; and the feature augmentation self-closed loop module constructs a negative supervision signal and dynamically corrects a disturbance perception and feature embedding path. The problems that current multi-omics data is high in dimension, large in redundancy and large in noise, key features are difficult to extract under limited samples, and model generalization is difficult to maintain are solved.

The invention relates to the technical field of medicinal liquor raw material screening, and discloses an efficient medicinal liquor raw material screening method. The method comprises the following steps: collecting raw material basic parameters of multiple candidate medicinal materials, extracting multi-modal characteristic data to identify the distribution state of effective components, and generating an efficacy characteristic spectrum; calling an active ingredient identification area in the drug effect characteristic spectrum, obtaining an active ingredient concentration interval pointed by a target efficacy and a drug effect duration threshold, detecting a matching difference and generating an efficacy deviation characteristic set; according to medicinal material numbers associated with the efficacy deviation feature set, extracting component release curves and efficacy peak time points in continuous batches, calculating a stability difference with a preset reference line, screening medicinal materials which do not reach the standard, and generating a medicinal material ratio dynamic adjustment table; and calling a reference ratio value in the medicinal material ratio dynamic adjustment table, monitoring a fusion state of the effective components in real-time preparation, marking a collaborative reaction starting time node of the three adjacent components, recording a collaborative activation state and generating a raw material combination optimization instruction.

The invention provides a traditional Chinese medicine preparation quality detection method and system based on multi-dimensional data analysis, and belongs to the technical field of traditional Chinese medicine preparation quality detection. The method comprises the following steps: acquiring mass spectrum data and nuclear magnetic resonance data of various active components in a preparation to generate a multi-dimensional chemical characteristic data set; synchronously collecting corresponding data of the medicinal raw materials, and constructing a process and environment association database; constructing a chemical and process coupling analysis model; and monitoring the production process in real time to obtain the dynamic chemical fingerprint spectrum. By constructing a full-component chemical map and associating the full-component chemical map with process and environmental parameters and combining clinical curative effect data to establish a drug effect and component response curved surface model, the limitation that only a few index components are concerned in traditional detection is broken through, so that a detection result can accurately reflect the multi-target and overall regulation characteristics of the traditional Chinese medicine preparation, and the detection accuracy is improved. The problem that the components are qualified but the curative effect is poor due to single detection dimension is avoided, and the relevance between quality detection and the clinical curative effect is remarkably improved.

The invention relates to the technical field of traditional Chinese medicine external preparations, in particular to a self-heating Chinese herbal medicine plaster and a preparation method thereof.The self-heating Chinese herbal medicine plaster sequentially comprises a heating layer, a temperature control isolation layer, a medicine storage layer, a medical pressure-sensitive adhesive layer and a release layer from top to bottom; the preparation method of the self-heating Chinese herbal medicine plaster comprises the following steps: coating the medical pressure-sensitive adhesive layer with the medicine storage layer, drying the medicine storage layer, sequentially overlapping the medicine storage layer with the prepared heating layer, the temperature control isolation layer and the release layer, compounding by adopting a full-automatic assembling machine, punching and forming, and independently packaging by adopting aluminum plastic, so as to obtain the self-heating Chinese herbal medicine plaster. The heating duration is lasting, the highest heating temperature is accurate and moderate, and the scalding risk is avoided. Various carefully-chosen Chinese herbal medicines are fused, the medicine effect of the Chinese herbal medicines is fully exerted, and the treatment effect of relieving pain and promoting rehabilitation is remarkable.

The invention discloses a compound fluralana external preparation for dogs, a preparation method and application, belongs to the technical field of veterinary drugs, and solves the problems that an existing preparation is poor in skin surface permeability, a solvent is easy to volatilize, and use experience and drug effect exertion are influenced. The preparation is prepared from the following raw materials: fluralana, moxidectin, ethyl butylacetamidopropionate and N, N-dimethylformamide. The preparation method comprises the following steps: adding N, N-dimethylacetamide, acetone, an auxiliary adjuvant, a transdermal penetration enhancer, an antioxidant and a surface film-forming agent; according to the invention, the combination of the fluralab and the moxidectin can play a synergistic effect and expand an anti-parasitic spectrum so as to achieve an internal and external driving effect; both the fluralab and the moxidectin belong to high-fat-soluble substances, parasites can be quickly repelled and killed by adding novel adjuvant natural parasite expelling ingredients, and meanwhile, the skin permeability can be improved by adding the efficient transdermal penetration enhancer, and the risk that medicine residues are licked by pets is reduced.

The invention provides a pharmaceutical composition for treating non-small cell lung cancer and application of the pharmaceutical composition. The pharmaceutical composition comprises gefitinib, erlotinib, afatinib, neratinib, osimertinib and the like which serve as active ingredients. The pharmaceutical composition disclosed by the invention can simultaneously contain various EGFR inhibitors as active ingredients, and the active ingredients are controlled at ultra-low dosage, so that the pharmaceutical composition not only can ensure the treatment effect, even the drug effect of the pharmaceutical composition is obviously superior to that of a high-dosage EGFR inhibitor independent administration group, but also can ensure the safety, and the pharmaceutical composition is suitable for clinical application. And after the active components are combined, a good synergistic effect is achieved, and more importantly, the occurrence of drug resistance can be remarkably reduced or even resisted. In a lung cancer cell culture experiment, the EGFR inhibitor independent administration group has a drug resistance phenomenon at the earliest 20 days, but the pharmaceutical composition group still has no drug resistance phenomenon after 160 days of administration.

A compound represented by formula (I), a stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition thereof, a preparation method therefor, and a use thereof. The compound has one or more of the following effects: (1) good KRAS G12C inhibitory activity; (2) good KRAS G12D inhibitory activity; (3) good KRAS G12V inhibitory activity; (4) optimal exposure dose; (5) good bioavailability; and (6) good in vivo efficacy.

The application relates to the technical field of cough-relieving medicines, and discloses a high-efficiency cough-relieving loquat particle composition which is composed of the following components in parts by weight: loquat leaf extract 30-40 parts; white front extract 10-15 parts; platycodon grandiflorum extract 6-10 parts; white mulberry bark extract 18-25 parts; stemona sessiliflora extract 7-10 parts; menthol 0.1-0.5 part; polyethylene glycol 2-5 parts; mannitol 8-12 parts; ethyl cellulose 3-6 parts; hydroxypropyl methyl cellulose 1-3 parts; phosphatidylcholine 1-3 parts; polysorbate 80 1-3 parts; cross-linked sodium carboxymethyl cellulose 4-6 parts; and sucrose 40-60 parts. The double dispersion system combining the immediate-release component and the sustained-release component is adopted, the solubility and the initial release speed of the traditional Chinese medicine extract are remarkably improved through the addition of polyethylene glycol and mannitol, and the technical effect that the drug effect appearing time is remarkably shortened is achieved. Compared with the technical scheme relying on only a single release mode in the prior art, the deficiency that the drug effect is slow and the symptoms of the patient cannot be timely relieved is solved.

The application provides a preparation method of a Chlorella-arsene composite drug delivery system and application thereof. The application prepares arsene nanosheets (ANs) through a liquid phase stripping method, and obtains catechol-polyethyleneimine nanoparticles (CA-PEI) through oxidation self-polymerization. The ANs and the CA-PEI are charge-absorbed to form CA-PEI loaded with ANs (CA-PEI@ANs), and then charge-absorbed with protein nucleus Chlorella (CP), so that a Chlorella-arsene composite drug delivery system (CP@CA-PEI@ANs) is successfully constructed. The preparation operation of the drug delivery system is simple, and the reproducibility is good, and the drug delivery system has a good application prospect. The protein nucleus Chlorella is used as a drug delivery carrier, so that the problems of high cost and complex synthesis process commonly existing in a targeted delivery carrier are solved, and the application has good tumor targeting effect, and is beneficial to better drug efficacy.

The invention discloses a traditional Chinese medicine liniment for treating rheumatoid arthritis and a preparation process thereof, the traditional Chinese medicine liniment is composed of a wind-dispelling and pain-relieving liquid medicine and auxiliary materials, the wind-dispelling and pain-relieving liquid medicine contains eight traditional Chinese medicines of thorny elaeagnus root, erythrina bark, kadsura longepedunculata root, waxberry root, ardisia crenata, rose mallow root, glabrous sarcandra herb and wikstroemia canescens root, and is prepared by ultrasonic extraction; the auxiliary materials comprise polyvinyl alcohol, a chitosan-acetic acid solution, glycerol, azone, methylparaben, vanillyl butyl ether and ethanol. The liniment is short in film forming time and good in stability, has excellent transdermal absorption performance and antioxidant activity, can remarkably relieve joint swelling of RA model mice, improve the pain threshold value, improve joint pathological injuries, achieve local precise long-acting administration, reduce side effects of the whole body and improve patient compliance, is suitable for clinical treatment of RA, and has a wide application prospect. The problems that an existing rheumatoid arthritis treatment medicine is large in side effect, and a traditional Chinese medicine preparation is short in efficacy duration and inconvenient to use are solved.

The present invention relates to a novel polymorph of (1R,2R,3aS,3bR,10aS,10bR,11S,12aS)-5,10b-difluoro-1-(((fluoromethyl)thio)carbonyl)-11-hydroxyl-2,10a,12a-trimethyl-7-phenyl-1,2,3,3a,3b,7,10,10a,10b,11,12,12a-dodecylhydrocyclapenta[5,6]napththo[1,2-F]indazole-1-furan-2-carboxylate ester as shown in formula (I), a preparation method therefor, and a use thereof. The crystal form of the present invention has characteristics such as a significant pharmaceutical effect, good stability, high yield, and high purity, and is beneficial for the selection and design of a drug administration route and the determination of a drug preparation process parameter, thereby improving drug production quality.

The invention relates to the technical field of medicines, and discloses an application of combination of bufalin and heme in preparation of a cancer treatment medicine. According to the invention, by means of an active metabonomics means, a key active metabolite-heme is locked through exogenous library screening and endogenous analysis, and the drug effect of bufalin is regulated by means of the active metabolite. Through verification, it is found that heme can cooperate with the synergistic drug effect in various cancer cell lines, and a new technical normal form based on an active metabolome for improving the drug effect of bufalin is provided. The pharmaceutical composition can improve the apoptosis induction ability of bufalin to different cancer cells, and provides powerful guiding significance for developing a novel treatment scheme in clinical medicine.

The invention discloses a method for detecting anions in a phlegm-heat-clearing injection, the detection method comprises the following steps: a test solution and a reference solution are taken for detection, the phlegm-heat-clearing injection is composed of scutellaria baicalensis, bear gall powder, cornu gorais, honeysuckle, fructus forsythiae and propylene glycol; chromatographic conditions of the detection are as follows: an anion exchange chromatographic column is adopted, an eluent is an acid aqueous solution, an alkali aqueous solution and / or a buffer salt aqueous solution, the flow velocity is 0.1-2.0 ml / min, the column temperature is 20-40 DEG C, a detector is an electrical conductivity detector, the detection mode is suppression electrical conductivity detection, and the sample size is 10-40 [mu] l; and obtaining the content information of the anions in the phlegm-heat clearing injection according to the detection result. The method disclosed by the invention is simple, convenient, efficient and rapid, and provides a theoretical basis for the quality control of the phlegm-heat clearing injection and the deep research of a pharmacodynamic material basis by detecting the content of the anions.

The present invention belongs to the field of biomedicine. Provided are an organic molecular self-assembly serving as a carrier-free system, and a preparation method therefor and the use thereof. Provided is a self-assembly, which is composed of steroidal molecules, and by means of optimizing the molecular structures of these steroids and critical aggregation concentrations thereof, a carrier-free system formed via self-assembly of the steroidal molecules is prepared. The carrier-free system can be loaded with a drug to prepare a drug nanocomposite. In the nanocomposite, the efficacy of the drug is improved, and the effects of reducing toxicity and improving efficacy can be achieved. If the steroid molecules used are themselves biologically active, the pharmacological activity of the steroid molecules remains unaffected after being prepared into the drug nanocomposite. The carrier-free system has the advantages of both a carrier-free nano-preparation and a nano-preparation using a conventional material as a carrier.

The invention relates to the technical field of medical care data processing, and discloses a medical care data processing method and system based on artificial intelligence, and the method comprises the steps: recording a medicine taking moment, a medicine effect starting moment and a medicine effect ending moment when a user takes medicines of each dose type; executing a work intensity evaluation strategy for each time period, monitoring the typewriting frequency of the user in each time period, and calculating the work intensity of each time period according to the time period score of the user; according to historical workdays, executing a drug effect intensity matching strategy, and calculating the corresponding work intensity of the drugs of each dose category under the optimal work completion degree; executing an intelligent medicine taking time period matching strategy, and calculating the optimal medicine taking time and dosage type based on the predicted working intensity of the next workday; and a night dose intelligent back-pushing module is executed, the dose type of the medicine taken before sleep in the next workday is calculated, the matching degree between the medicine use and the work performance is improved, and the work efficiency and the state stability are maintained to the maximum extent.

The invention belongs to the technical field of biomedicine, and particularly relates to an animal model and a modeling method thereof. According to the method, the northwest dryness syndrome type sub-health animal model is successfully constructed, an open model evaluation mode is adopted, and the established model is evaluated through goodness of fit; furthermore, autumn pear syrup is used for indicating that the prescription corresponds to the syndrome. The northwest dryness syndrome type sub-health target model established by the invention can provide a stable and reliable research model for external dryness syndrome essence exploration, arid region sub-health prevention and treatment, drug effect and pharmacological mechanism research of traditional Chinese medicines, prescriptions and the like with body resistance strengthening and dryness moistening effects, health product research and development and the like. An open model evaluation mode is adopted, and the higher the goodness of fit is, the closer the model to the northwest dryness syndrome type sub-health target model is. The northwest dryness syndrome type square domain dryness evil sub-health rat model is more suitable for arid region sub-health status research, and the northwest dryness syndrome type autumn cause dryness evil sub-health rat model is more suitable for autumn moistening health care research.

The invention provides application of an SNP (Single Nucleotide Polymorphism) marker of MIA2 in predicting the curative effect of an antithrombotic drug on thrombus, and belongs to the fields of molecular biology and cardiovascular medicine. According to the application disclosed by the invention, one or more of rs11845046 and rs10134365 of the MIA2 gene is found to be related to the prediction of the curative effect of dabigatran on thrombus for the first time. Gene polymorphism analysis and an ROC curve verify that the curative effect of an NVAF patient after the NVAF patient is treated by using the antithrombotic drug is related to the genotypes of rs11845046 and rs10134365 of the MIA2 gene in a patient sample, and when the genotype of the rs11845046 is GG or the genotype of the rs10134365 is CC, the drug effect of the subject taking the antithrombotic drug is good but the probability of bleeding events is increased.

This invention discloses a GLP-1 peptide drug microneedle and its preparation method. The microneedle is composed of PVP, NVP, a photoinitiator, and a GLP-1 receptor agonist. The preparation method includes two steps: material preparation and peptide microneedle patch preparation. First, a certain amount of PVP is dissolved in NVP to prepare a solution with appropriate specific gravity and viscosity. Then, the photoinitiator and GLP-1 receptor agonist are added to the solution to form a liquid system that is as uniformly suspended as possible. Second, the suspension is filled into a microneedle mold, and NVP is polymerized into solid PVP by ultraviolet light irradiation. Under the constraint of the mold, the solid PVP forms the geometric shape of the microneedle. Subsequently, a small amount of NVP is spread evenly on the backing layer of the microneedle and covered with a plastic film. Ultraviolet light irradiation is applied again to crosslink the plastic film with the PVP microneedle, and the microneedle is then peeled out of the mold. The advantage of this application is that it uses PVP to prepare an NVP solution with suitable specific gravity and viscosity, so that the subsequently added drug is uniformly suspended in the solution, thereby improving the uniformity of drug loading on microneedles and increasing the drug loading capacity, which is beneficial to improving the efficacy and consistency of drug efficacy.